USPSTF Updated Recommendations for Cervical Cancer Screening
The US Preventive Services Task Force (USPSTF) has updated its recommendation on screening for cervical cancer, the recommendations have been published recently in JAMA.

There is a small difference between the final recommendations and the draft guidelines that were released last year. The difference relates to the recommendation on cotesting (details below).

Screening with cytology alone every 3 years for women aged 21 to 65 years (grade A recommendation) continues to be recommended, but for the first time, the USPSTF now recommends a stand-alone test for high-risk types of human papillomavirus (hrHPV) in women aged 30 to 65 years (grade A recommendation).

Of note, in contrast to the task force's position in their earlier draft, the final update continues to recommend cytology plus hrHPV cotesting every 5 years for women aged 30 to 65 years (grade A recommendation).

However, cotesting is considered an "alternative" strategy as opposed to the "preferred" use of cytology or hrHPV testing alone. The USPTF notes that although cotesting has been demonstrated to be similar in effectiveness to cytology or hrHPV testing, its use may result in more tests and procedures as compared with either cytology or hrHPV testing alone.

Read more here:

Original article can be read here:
Dr. R●●a B●●●●●●●y and 1 others like this4 shares